Introduction and aims
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
- Natural history of ischemic heart disease in relation to arteriographic findings: a twelve year study of 224 patients.Circulation. 1974; 49: 489-497
- Coronary plaque disruption.Circulation. 1995; 92: 657-671
- Rapid angiographic progression of coronary artery disease in patients with angina pectoris The role of complex stenosis morphology.Circulation. 1995; 92: 2058-2065
- The pathogenesis of coronary artery disease and the acute coronary syndromes (1).N Engl J Med. 1992; 326: 242-250
- C-Reactive protein concentrations and angiographic characteristics of coronary lesions.Clin Chem. 2001; 47: 882-886
- Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris.Circulation. 2004; 110: 1747-1753
Ischaemic heart disease registers. Report of the fifth Working Group convened by the Regional Office for Europe of the World Health Organization. Copenhagen, April 1971. Regional Office for Europe. Geneva: World Health Organization. 1971.
- Unstable angina a classification.Circulation. 1989; 80: 410-414
- Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes.Heart. 2004; 90: 847-852
- Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.Eur Heart J. 2005; 26: 457-463
- A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors.Am Heart J. 1990; 119: 1262-1267
- Stability and instability: two faces of coronary atherosclerosis The Paul Dudley White Lecture 1995.Circulation. 1996; 94: 2013-2020
- Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: a study based on four serial coronary arteriograms per year.Circulation. 1999; 100: 903-909
- Prognostic and clinical correlates of angiographically diffuse non-obstructive coronary lesions.Heart. 2003; 89: 1009-1013
- C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina.J Am Coll Cardiol. 2002; 39: 632-637
- C-reactive protein elevation and disease activity in patients with coronary artery disease.Eur Heart J. 2004; 25: 401-408
- Preoperative C-reactive protein levels predict 9-month mortality after coronary artery bypass grafting surgery for the treatment of left main coronary artery stenosis.Eur J Cardiothorac Surg. 2007; 31: 685-690
- Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials.BMJ. 2000; 321: 73-77
RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997; 350(9076):461–68.
- Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.J Am Coll Cardiol. 2003; 42: 1161-1170
- The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results.J Am Coll Cardiol. 2004; 43: 1743-1751
- Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials.Circulation. 2004; 110: 1226-1230
- Optimal medical therapy with or without PCI for stable coronary disease.N Engl J Med. 2007; 356: 1503-1516
- C-reactive protein levels and outcomes after statin therapy.N Engl J Med. 2005; 352: 20-28
- Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA. 2006; 295: 1556-1565
- Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.J Am Coll Cardiol. 2005; 45: 1644-1648
- Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.J Am Coll Cardiol. 2005; 46: 1411-1416